Patricia Inácio, PhD, science writer —

Intrance Medical Systems has raised $8 million to support a planned U.S. clinical trial of its fixed-dose combination of levodopa, carbidopa, and entacapone in advanced Parkinson’s disease patients. The combo therapy, originally developed by Lobsor Pharmaceuticals and sold under the name Lecigon in Nordic countries —  Denmark, Finland, Iceland, Norway and Sweden, and their…

Top-line results are expected to be released by the end of this year for Pharma Two B’s multinational trial investigating the safety and efficacy of P2B001 for treating early stage Parkinson’s disease. Pharma Two B announced that its researchers have finished treating patients in the Phase 3 trial, which…

Several new clinical trial data analyses support the benefits and superiority of Gocovri (amantadine) over other therapies in lessening off episodes — periods when levodopa treatments stop working and motor symptoms return — and involuntary movements called dyskinesia in people with Parkinson’s disease. These analyses compared Gocovri, marketed by…

TreeFrog Therapeutics has raised $75 million in financing to support the clinical development of its stem cell-derived cell therapies for Parkinson’s disease, the company said in a press release. The new financing round, which brings the total funding to date to $83 million, will allow the company to use…

High prices, lack of access, and long waiting times are major barriers to people who want to undergo genetic testing for Parkinson’s disease, according to a survey by the International Parkinson and Movement Disorder Society (MDS). Survey results will be presented at the MDS Virtual Congress 2021, held…

The majority of Parkinson’s patients given Sunovion‘s Kynmobi (apomorphine hydrochloride) for “off” episodes during Phase 3 clinical trials did not require additional treatment for vomiting or nausea, the company said. Indeed, an analysis found that nearly 90% of participants reached the optimal dose of Kynmobi in trials without…

A potential Parkinson’s  therapy based on a protein with an ability to protect neurons — called recombinant (lab-made) human cerebral dopamine neurotrophic factor (rhCDNF) — has been transformed into tiny nanoparticles that may allow for its use as a nasal spray, Herantis Pharma,…

One in three people with early to mid-stage Parkinson’s disease were found to have difficulties in learning a new task by following instructions. The deficits were more prone during the early stages of learning, when new memories are being made, and were linked to poorer activation of certain brain…

A non-invasive test that measures signals from the olfactory bulb — the part of the brain responsible for scent-perception — may aid in the early diagnosis of Parkinson’s disease, according to a recent study. The test, called an electrobulbogram, also also can inform about disease duration, severity, and the…

A medicine approved to treat attention deficit hyperactivity disorder (ADHD), called atomoxetine, could help to improve thinking and impulse control in certain people with Parkinson’s disease, a small study suggests. Patients with the greatest loss of integrity in a part of the brainstem called locus coeruleus, evident on a brain scan,…